Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash ...

Key market opportunities in CD137-targeted therapies include the upcoming commercial launch by 2030, robust clinical trial activity with over 90 therapies, and promising combination therapies.

FOSHAN, GUANGDONG, CHINA, January 14, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

The movement of waves, patterns that carry sound, light or heat, through materials has been widely studied by physicists, as ...

Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...

In January 2022, Garutadustat, the innovative, potentially best-in-class, oral PHD inhibitor was nominated as a preclinical ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Track bar adjustments sound like garage jargon until you see how much they change the car’s balance. On a NASCAR stock c ...

Currently, Kyocera’s technology enables aerial images whose focal positions vary by wavelength. In the future, increasing the ...